natgillin/translations-raw huggingface dataset:
Alle materialer, der har været i kontakt med Imlygic (fx hætteglas, sprøjte, kanyle, vat eller servietter), skal kasseres i overensstemmelse med institutionens procedurer.
Dispose of all materials that have come in contact with Imlygic (e.g. vial, syringe, needle, any cotton or gauze) in accordance with local institutional procedures.
Alle metabolitter, der er set i urin, fæces og plasma efter en intravenøs 100 mg dosis af [14C] fosaprepitant, sås også efter en oral dosis af [14C] aprepitant.
All metabolites observed in urine, faeces and plasma following an intravenous 100 mg [14C]- fosaprepitant dose were also observed following an oral dose of [14C]-aprepitant.
Alle mykologisk bekræftet
All mycologically confirmed
Alle mykotisk bekræftet
All mycologically confirmed
Alle p-værdier er justeret for testmultiplicitet ud fra prædefineret hierarki, bortset fra ACR70, dactylitis og enthesitis, som var eksplorative endepunkter.
All p-values are adjusted for multiplicity of testing based on pre-defined hierarchy, except for ACR70, Dactylitis and Enthesitis, which were exploratory endpoints.
Alle p-værdier er justeret for testmultiplicitet ud fra prædefineret hierarki, bortset fra BASDAI 50 og ASDAS-CRP
All p-values adjusted for multiplicity of testing based on pre-defined hierarchy, except BASDAI 50 and ASDAS-CRP
Alle p-værdier er parvise sammenligninger af andelene for Humira vs. placebo
All p-values are pairwise comparisons of proportions for Humira versus placebo
Alle p-værdier er parvise sammenligninger af forholdet for Trudexa vs. placebo
All p-values are pairwise comparisons of proportions for Trudexa versus placebo
Alle pakninger fås i PVC/PCTFE – Aluminium blister.
All packs are available in PVC/PCTFE - Aluminium blisters.
Alle pakninger på nær 150 ml flasken har vedlagt en måleske, mærket med doserne 2,5 ml og 5 ml.
For all packages except the 150 ml bottle, a measuring spoon is provided, marked for doses of 2.5 ml and 5 ml.
Alle pakningsstørrelser er ikke nødvendigvis markedsført.
Not all pack sizes may be marketed.
Alle pakningsstørrelser findes med eller uden kanyle(r).
All pack sizes are available with or without needle(s).
Alle pakningsstørrelser markedsføres ikke nødvendigvist.
Not all pack sizes may be marketed.
Alle pakningstørrelser er muligvis ikke markedsført.
Not all pack sizes may be marketed.
Alle papillomavira har en skal eller et "kapsid", der består af særlige proteiner kaldet "L1-proteiner".
All papillomaviruses have a shell or ‘capsid’, which is made up of distinctive proteins called ‘L1 proteins’.
Alle papillomavira har en skal, eller et »kapsid«, der består af proteiner, som kaldes »L1-proteiner«.
All papillomaviruses have a shell, or ‘capsid’, that is made up of proteins called ‘L1 proteins’.
Alle papillomavirus har en skal (et capsid) bestående af L1-proteiner.
All papillomaviruses have a shell, or ‘capsid’, that is made up of proteins called ‘L1 proteins’.
Alle partielle
All partial
Alle patientbrochurer bør indeholde følgende oplysninger:
All booklets should contain the following information
Alle patienter
All Subjects
Alle patienter
For all patients
Alle patienter
Overall population
Alle patienter (N=39)
All patients (N=39)
Alle patienter (N=449) (%)
All Patients (N=449) (%)
Alle patienter 50% (42–58)
All patients 50% (42–58)
Alle patienter 63% (56–71)
All patients 63% (56–71)
Alle patienter 69% (58–79)
All patients 69% (58–79)
Alle patienter begyndte med 50 mg eltrombopag.
All patients initiated treatment with eltrombopag 50 mg.
Alle patienter behandlet med MabThera for reumatoid artrit, granulomatose med polyangiitis eller mikroskopisk polyangiitis skal have udleveret patientkortet ved hver infusion.
All patients treated with MabThera for rheumatoid arthritis, granulomatosis with polyangiitis and microscopic polyangiitis must be given the patient alert card with each infusion.
Alle patienter blev efterfølgende optaget i en open- label forlængelsesstudie, hvor de alle fik 100 E/kg Aldurazyme hver uge i yderligere 3,5 år (182 uger).
All patients subsequently enrolled in an open label extension study where they all received 100 U/kg of Aldurazyme every week for an additional 3.5 years (182 weeks).
Alle patienter blev også behandlet med ASA i mindst 30 dage.
All patients were also treated with ASA for at least 30 days.
Alle patienter bør desuden have et adækvat jerntilskud (f.eks.
In addition, all patients should receive adequate iron supplementation (e.g.
Alle patienter bør få undervisning af lægen eller sundhedspersonalet i, hvordan de skal anvende Airexar Spiromax.
All patients should be provided with training by the prescribing Health Care Professional on how to use Aerivio Spiromax.
Alle patienter bør grundigt informeres om, at kardiovaskulære risici skal monitoreres med regelmæssige intervaller, sædvanligvis hver 6. til 12. måned.
All patients should be fully informed that cardiovascular risks should be monitored on a regular basis generally every 6-12 months.
Alle patienter bør have ASA umiddelbart efter diagnosticering af akut STEMI, såfremt der ikke er kontraindikationer (i en dosis på 75 mg-325 mg en gang dagligt).
All patients should receive ASA immediately after the diagnosis of acute STEMI as long as there will be no contraindications (the medicinal product is administered at a dose of 75 mg to 325 mg once daily).
Alle patienter bør have ASA umiddelbart efter diagnosticering af akut STEMI, såfremt der ikke er kontraindikationer (i en dosis på 75-325 mg en gang dagligt).
All patients should receive ASA immediately after the diagnosis of acute STEMI as long as there will be no contraindications (the medicinal product is administered at a dose of 75 mg to 325 mg once daily).
Alle patienter bør indgives ASA umiddelbart efter diagnosticeringen af akut STEMI, såfremt der ikke er kontraindikationer (i en dosis på 75- 325 mg en gang dagligt).
All patients should receive ASA immediately after the diagnosis of acute STEMI as long as there will be no contraindications (the medicinal product is administered at a dose of 75 mg to 325 mg once daily).
Alle patienter bør indgives ASA umiddelbart efter diagnosticeringen af akut STEMI, såfremt der ikke er kontraindikationer (lægemidlet administreres i en dosis på 75 mg til 325 mg en gang dagligt).
All patients should receive ASA immediately after the diagnosis of acute STEMI as long as there will be no contraindications (the medicinal product is administered at a dose of 75 mg to 325 mg once daily).
Alle patienter bør opfordres til at opretholde en god mundhygiejne, gennemgå rutinemæssige tandeftersyn og straks rapportere eventuelle orale symptomer såsom tandmobilitet, smerter eller hævelse eller vedvarende sår eller sekretion under behandling med Zometa.
All patients should be encouraged to maintain good oral hygiene, undergo routine dental check-ups, and immediately report any oral symptoms such as dental mobility, pain or swelling, or non-healing of sores or discharge during treatment with Zoledronic Acid Teva.
Alle patienter bør præmedicineres med en H1-antagonist (f.eks. diphenhydramin) og dexamethason (eller tilsvarende lægemidler) intravenøst 30-60 minutter forud for olaratumab-doserne på dag 1 og dag 8 i serie 1.
Premedication with an H1 antagonist (e.g., diphenhydramine) and dexamethasone (or equivalent medicinal products) should be given, intravenously, 30–60 minutes prior to the olaratumab doses on days 1 and 8 of cycle 1 in all patients.
Alle patienter bør påbegynde behandling med dexamethason 4 mg 2 gange dagligt, enten oralt eller intravenøst, i 5 dage, startende på dagen for DepoCyte injektionen.
All patients should be started on dexamethasone 4 mg twice daily either orally or intravenously for 5 days beginning on the day of injection of DepoCyte.
Alle patienter bør samtidigt behandles med et antikoagulerende middel (et lægemiddel, som forebygger dannelsen af blodpropper) i mindst de første fem måneder af behandlingen, men dette afhænger af en grundig risikovurdering for hver enkelt patient.
Each patient should also receive an anticoagulant (a medicine to prevent the formation of blood clots) for at least the first five months of treatment, after careful assessment of the patient’s individual risk.
Alle patienter bør screenes for HBV før påbegyndelse af MabThera-behandling.
Hepatitis B virus (HBV) screening should be performed in all patients before initiation of treatment with MabThera.
Alle patienter bør screenes for hepatitis B, inden behandling med Gazyvaro påbegyndes.
Hepatitis B virus screening should be performed in all patients before initiation of treatment with Gazyvaro.
Alle patienter bør screenes for hepatitis B-virus (HBV) før påbegyndelse af behandling med MabThera.
Hepatitis B virus (HBV) screening should be performed in all patients before initiation of treatment with MabThera.
Alle patienter bør starte med dexamethason 4 mg 2 gange daglig enten peroralt eller intravenøst i 5 dage begyndende fra dagen for DepoCyte injektionen.
All patients should be started on dexamethasone 4 mg twice daily either orally or intravenously for 5 days beginning on the day of DepoCyte injection.
Alle patienter bør undersøges rutinemæssigt for hypertension og behandles efter behov.
All patients should be routinely evaluated for hypertension and treated as needed.
Alle patienter der behandles med eculizumab modtager et patientsikkerhedskort
All patients being treated with eculizumab receive a patient safety card.
Alle patienter fik 150 mg dabigatranetexilat 2 gange dagligt.
All patients received doses of 150 mg twice daily of dabigatran etexilate.
Alle patienter fik Cosentyx i doser på 150 mg eller 300 mg i ugerne 0, 1, 2, 3, 4, 8 og 12 og blev derefter randomiseret til at få enten et vedligeholdelsesregime med samme dosis hver måned med start i uge 12, eller et ”behandling efter behov”-regime med samme dosis.
All patients received Cosentyx 150 mg or 300 mg doses at Weeks 0, 1, 2, 3, 4, 8 and 12 and then were randomised to receive either a maintenance regimen of the same dose every month starting at Week 12 or a “retreatment as needed” regimen of the same dose.
Alle patienter fik dabigatranetexilatdosis på 150 mg 2 gange dagligt.
All patients received doses of 150 mg twice daily of dabigatran etexilate.
Alle patienter fik en total dosis cisplatin på 480 mg/m2 som en del af deres induktions- (neoadjuvant) og/eller vedligeholdelses- (adjuvant) kemoterapiregime.
All patients received a total dose of cisplatin of 480 mg/m2 as part of their induction (neoadjuvant) and/or maintenance (adjuvant) chemotherapy regimen.
Alle patienter fik methotrexat (optimeret til 20 mg/uge ved uge 8) og enten placebo, 3 mg/kg eller 6 mg/kg infliximab i ugerne 0, 2 og 6 samt hver 8. uge derefter.
Infliximab was administered at a dose of 5 mg/kg at weeks 0, 2, 6, and then every 8 weeks.
Alle patienter fik mindst to års enzymerstatningsterapi og blev fulgt i gennemsnitligt 4,5 år (min.
All patients received at least 2 years of ERT and were followed for a mean of 4.5 years (min.
Alle patienter fik også ASA i mindst 30 dage.
All patients were also treated with ASA for at least 30 days.
Alle patienter fik Soliris, og i undersøgelsen blev det registreret, hvor mange transfusioner af røde blodlegemer der var nødvendige i løbet af de 12 ugers behandling.
All patients received Soliris and the study measured the number of red blood cell transfusions needed during the 12 weeks of treatment.
Alle patienter fik standardbehandling og blev randomiseret til enten placebo eller eptifibatid (2 bolus- doser på 180 mikrogram/kg og en kontinuerlig infusion indtil udskrivelse fra hospitalet eller højst 18- 24 timer).
All patients received routine standard of care and were randomised to either placebo or eptifibatide (2 bolus doses of 180 microgram/kg and a continuous infusion until discharge from hospital or a maximum of 18-24 hours).
Alle patienter fik Tagrisso i en dosis på 80 mg én gang dagligt.
All patients received TAGRISSO at a dose of 80 mg once daily.
Alle patienter forblev følsomme for tenofovir.
All patients remained susceptible to tenofovir.
Alle patienter får en stærk rødfarvning af urinen i de første tre dage efter behandlingen.
All patients will show a dark red colouration of the urine quite marked during the three days following administration.
Alle patienter havde haft utilstræ kkelig effekt af tidligere konventionel behandling.
All patients had experienced an inadequate response to prior conventional therapies.
Alle patienter havde haft utilstrækkelig virkning af tidligere konventionel behandling.
Approximately 93% of the patients had previously received antibiotic or immunosuppressive therapy.
Alle patienter i de udvalgte kliniske forsøg af kronisk hepatitis C fik foretaget leverbiopsi før inklusion, men i visse tilfælde (for eksempel patienter med genotype 2 og 3), kan behandling være mulig uden histologisk verifikation.
All patients in the selected chronic hepatitis C studies had a liver biopsy before inclusion, but in certain cases (i.e. patients with genotype 2 and 3), treatment may be possible without histological confirmation.
Alle patienter i de valgte undersøgelser af kronisk hepatitis C-undersøgelserne fik foretaget en leverbiopsi før inklusion, men i visse tilfælde (eksempelvis patienter med genotype 2 og 3) kan behandling være mulig uden histologisk bekræftelse.
All patients in selected chronic hepatitis C studies had a liver biopsy before inclusion, but in certain cases (i.e. patients with genotype 2 and 3), treatment may be possible without histological confirmation.
Alle patienter i dette studie havde tidligere oplevet behandlingssvigt på et proteasehæmmerregime (defineret som plasma hiv-1-RNA som aldrig kom under 1.000 kopier/ml efter mindst 12 konsekutive ugers behandling, eller som initial suppression af hiv-1-RNA med efterfølgende rebound til  1.000 kopier/ml).
All patients in this study had failed treatment with a previous protease inhibitor regimen (defined as plasma HIV-1 RNA that never went below 1,000 copies/ml after at least 12 consecutive weeks of therapy, or initial suppression of HIV-1 RNA which subsequently rebounded to  1,000 copies/ml).
Alle patienter i dette studie havde tidligere oplevet behandlingssvigt på et proteasehæmmerregime (defineret som plasma-hiv-1-RNA som aldrig kom under 1.000 kopier/ml efter mindst 12 konsekutive ugers terapi, eller som initial suppression af hiv-1-RNA med efterfølgende rebound til  1.000 kopier/ml).
All patients in this study had failed treatment with a previous protease inhibitor regimen (defined as plasma HIV-1 RNA that never went below 1,000 copies/ml after at least 12 consecutive weeks of therapy, or initial suppression of HIV-1 RNA which subsequently rebounded to  1,000 copies/ml).
Alle patienter kom sig uden følgevirkninger.
All patients recovered without sequelae.
Alle patienter med colitis ulcerosa, som har forhøjet risiko for dysplasi eller colon cancer (for eksempel patienter med langvarig colitis ulcerosa eller primæ r sklerotisk cholangitis), eller som tidligere har haft dysplasi eller colon cancer, bør screenes for dysplasi med regelmæ ssige intervaller før behandling og under deres sygdomsforløb.
All patients with ulcerative colitis who are at increased risk for dysplasia or colon carcinoma (for example, patients with long-standing ulcerative colitis or primary sclerosing cholangitis), or who had a prior history of dysplasia or colon carcinoma should be screened for dysplasia at regular intervals before therapy and throughout their disease course.
Alle patienter med frameshift (læserammeskift)/splice site (splejsningssekvens)- mutationsgenotype udviklede antistoffer, og 4/6 blev også testet positive for neutraliserende antistoffer ved mindst 3 på hinanden følgende besøg.
All patients with the frameshift/splice site mutation genotype developed antibodies and 4/6 also tested positive for neutralizing antibodies on at least 3 consecutive study visits.
Alle patienter modtog også standardlægemidler til behandling af antithrombocyt.
All patients also received standard antiplatelet medicines.
Alle patienter N = 74
All patients N = 74
Alle patienter og forældre/plejere skal informeres om, at hvis patienten udvikler tegn eller symptomer, som kan pege på bloddyskrasi eller infektioner (f.eks. vedvarende feber, øm hals, blå mærker, blødning, bleghed) mens de er i behandling med Enbrel, skal de omgående søge læge.
All patients and parents/caregivers should be advised that if the patient develops signs and symptoms suggestive of blood dyscrasias or infections (e.g., persistent fever, sore throat, bruising, bleeding, paleness) whilst on Enbrel, they should seek immediate medical advice.
Alle patienter og forældre/plejere skal informeres om, at hvis patienten udvikler tegn eller symptomer, som kan pege på bloddyskrasi eller infektioner (f.eks. vedvarende feber, øm hals, blå mærker, blødning, bleghed), mens de er i behandling med Enbrel, skal de omgående søge læge.
All patients and parents/caregivers should be advised that if the patient develops signs and symptoms suggestive of blood dyscrasias or infections (e.g., persistent fever, sore throat, bruising, bleeding, paleness) whilst on Enbrel, they should seek immediate medical advice.
Alle patienter og specielt patienter, som tidligere har fået omfattende immunsuppresiv behandling, og psoriasis-patienter, der tidligere har været behandlet med PUVA, skal undersøges for ikke-melanom hudkræft inden og under behandling med Humira.
All patients, and in particular patients with a medical history of extensive immunosuppressant therapy or psoriasis patients with a history of PUVA treatment should be examined for the presence of non- melanoma skin cancer prior to and during treatment with Humira.
Alle patienter og specielt patienter, som tidligere har fået omfattende immunsuppresiv behandling, og psoriasispatienter, der tidligere har været behandlet med PUVA, skal undersøges for ikke-melanom hudkræft inden og under behandling med Humira.
All patients, and in particular patients with a medical history of extensive immunosuppressant therapy or psoriasis patients with a history of PUVA treatment should be examined for the presence of non- melanoma skin cancer prior to and during treatment with Humira.
Alle patienter og specielt patienter, som tidligere har fået omfattende immunsuppressiv behandling, og psoriasis-patienter, der tidligere har været behandlet med PUVA, skal undersøges for ikke- melanom hudkræft inden og under behandling med Humira.
All patients, and in particular patients with a medical history of extensive immunosuppressant therapy or psoriasis patients with a history of PUVA treatment should be examined for the presence of non- melanoma skin cancer prior to and during treatment with Humira.
Alle patienter opfyldte Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM IV) diagnostiske kriterier for bipolar I lidelse, aktuel manisk episode (DSM-IV 296,4x) eller blandingstilstand (DSM-IV 296,6x) og havde en Young Mania Rating Scale (YMRS) score på ≥ 20 ved screening og baseline.
All patients met the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) diagnostic criteria for bipolar I disorder, current episode manic (DSM-IV 296.4x), or mixed (DSM-IV 296.6x) and had a Young Mania Rating Scale (Y-MRS) score of ≥ 20 at screening and baseline.
Alle patienter opfyldte Rome II-kriterierne for IBS-C med en middel abdominal smertescore på ≥ 3 på en numerisk 0-10 punktsskala (kriterier som svarer til en population med moderat til svær grad af IBS), < 3 spontane afføringer med komplet tømning af rectum og ≤ 5 SBM'er om ugen i en 2-ugers baseline-periode.
All patients met Rome II criteria for IBS-C and were required to report a mean abdominal pain score of ≥ 3 on a 0-to-10-point numeric rating scale (criteria that correspond to a moderate to severe IBS population), < 3 complete spontaneous bowel movements and ≤ 5 SBMs per week during a 2-week baseline period.
Alle patienter oplevede symptomer relateret til catumaxomabs virkningsmekanisme med en sikkerhedsprofil, der af natur var sammenlignelig med den første intraperitoneale behandlingscyklus.
All patients experienced symptoms related to catumaxomab mode of action with a safety profile comparable in nature to the first i.p. treatment cycle.
Alle patienter overvåges for eventuelle reaktioner under infusionen og i mindst en til to timer efter.
All patients are monitored for any reactions during the infusion and for at least one to two hours afterwards.
Alle patienter på dosen 400/100 mg to gange daglig skiftede til et åbent studie af Kaletra mellem uge 48 og uge 72.
All patients converted to open-label Kaletra at the 400/100 mg twice daily dose between week 48 and week 72.
Alle patienter på dosen 400/100 mg to gange daglig skiftede til åbent studie af Kaletra mellem uge 48 og uge 72.
All patients converted to open-label Kaletra at the 400/100 mg twice-daily dose between week 48 and week 72.
Alle patienter skal have et tilstrækkeligt tilskud af calcium og vitamin D. Anafylaktisk reaktion/shock
All patients must receive adequate supplemental calcium and vitamin D. Anaphylactic reaction/shock
Alle patienter skal have indgivet kortikosteroider f.eks.
All patients must receive corticosteroids e.g.
Alle patienter skal have målt deres CPK-niveau, når behandlingen indledes og derefter med jævne mellemrum, særligt hvis de har kendte risikofaktorer for muskelskader.
All patients must have their CPK levels measured at the beginning of their treatment and at regular intervals, particularly if they have any known risk factors for muscle damage.
Alle patienter skal igennem udvidede oftalmologiske undersøgelser ved start og mindst hver 6. måned.
All patients should undergo comprehensive ophthalmological examinations at baseline and at least every six months, which should include visual acuity, slit-lamp examination, dilated fundus photography, and macular OCT imaging.
Alle patienter skal informeres om at søge læ ge, hvis sygdomstegn/symptomer, der tyder på tuberkulose (fx vedvarende hoste, skranten/væ gttab, let feber), forekommer under eller efter Flixabibehandling.
All patients should be informed to seek medical advice if signs/symptoms suggestive of tuberculosis (e.g. persistent cough, wasting/weight loss, low-grade fever) appear during or after Flixabi treatment.
Alle patienter skal informeres om at søge læge, hvis sygdomstegn/symptomer, der tyder på tuberkulose (vedvarende hoste, skranten/vægttab, let feber), forekommer under eller efter Inflectra- behandling.
All patients should be informed to seek medical advice if signs/symptoms suggestive of tuberculosis (e.g. persistent cough, wasting/weight loss, low-grade fever) appear during or after Inflectra treatment.
Alle patienter skal informeres om at søge læge, hvis sygdomstegn/symptomer, der tyder på tuberkulose (vedvarende hoste, skranten/vægttab, let feber), forekommer under eller efter Remsima- behandling.
All patients should be informed to seek medical advice if signs/symptoms suggestive of tuberculosis (e.g. persistent cough, wasting/weight loss, low-grade fever) appear during or after Remsima treatment.
Alle patienter skal informeres om at søge læge, hvis tegn eller symptomer, der tyder på tuberkulose (fx vedvarende hoste, vægttab, let feber) opstår under behandling med Ilaris.
All patients should be instructed to seek medical advice if signs or symptoms suggestive of tuberculosis (e.g. persistent cough, weight loss, subfebrile temperature) appear during Ilaris therapy.
Alle patienter skal informeres om at undgå kronisk eller akut overforbrug af alkohol, mens de får eluxadolin.
All patients should be instructed to avoid chronic or acute excessive alcohol use while taking eluxadoline.
Alle patienter skal jævnligt monitoreres klinisk for atrieflimren.
Periodically monitor all patients clinically for atrial fibrillation.
Alle patienter skal også før påbegyndelse af behandlingen have vurderet deres nyrefunktion for at udelukke patienter med stærkt nedsat nyrefunktion, og denne vurdering skal gentages under behandlingen, hvis der er mistanke om forværring.
In all patients, kidney function should also be assessed before starting treatment to exclude patients with severely reduced kidney function, and should be re-assessed during treatment if any worsening is suspected.